title: Safety and Efficacy of Zonisamide in Patients with Epilepsy: A Post-Marketing Surveillance Study.
abstract: OBJECTIVE
  Zonisamide (ZNS) is one of new antiepileptic drug, which is known to inhibit seizure through multiple mechanisms of action. In Korea, ZNS was approved as an antiepileptic drug in 1992 and has been used for epilepsy patients with partial and generalized seizures. The objective of this study was to investigate the efficacy and tolerability of ZNS in patients with epilepsy and to identify the incidence of adverse events in real clinical setting.
  
  
  METHODS
  This study was carried out in patients who received ZNS for epilepsy. Patients who were observed for at least 12 weeks after treatment with ZNS were included as evaluable subjects. Information regarding the status and type of adverse events occurring during the course of treatment with ZNS was obtained regardless of causal relationship to ZNS and efficacy was assessed by the study physicians and patients at 12 weeks post dose of ZNS.
  
  
  RESULTS
  A total of 1,948 patients were included in the study, and ZNS efficacy was evaluated in 1,744 patients. ZNS was used as a monotherapy in 1,095 patients and as an adjunctive drug in 853 patients. Of the total patients, 1,345 (69.1%) patients had partial seizure, 563 patients had generalized seizure, and 40 patients were undetermined. Adverse events were reported in 65 patients (3.34%) including 1 case of Stevens-Johnson syndrome, but no incidence of serious unexpected adverse drug reactions were reported. 755 patients (43.29%) became seizure free with ZNS treatment, and additional 322 patients (18.41%) experienced marked improvement with ZNS treatment.
  
  
  CONCLUSIONS
  Our study shows the safety and tolerability of ZNS treatment in patients with epilepsy in real clinical setting. In addition, ZNS was found to be an effective option as a monotherapy or in patients with generalized seizure.
authors.affiliation: Department of Neurology, Konkuk University School of Medicine, Seoul, Korea.
authors.forename: Hye Jin
authors.initials: HJ
authors.lastname: Lee
authors.affiliation: Medical Department, Eisai Korea Inc., Seoul, Korea.
authors.forename: Jeong Min
authors.initials: JM
authors.lastname: Son
authors.affiliation: Medical Department, Eisai Korea Inc., Seoul, Korea.
authors.forename: Jihee
authors.initials: J
authors.lastname: Mun
authors.affiliation: Department of Neurology, Konkuk University School of Medicine, Seoul, Korea.
authors.forename: Dong Wook
authors.initials: DW
authors.lastname: Kim
keywords: Epilepsy; Post-marketing surveillance; Zonisamide
references.citation: Clin Neuropharmacol. 2014 Sep-Oct;37(5):133-5
references.pmid: 25229169
references.citation: Acta Neurol Scand Suppl. 2012;(194):29-35
references.pmid: 23106523
references.citation: Epilepsia. 2005 Jan;46(1):31-41
references.pmid: 15660766
references.citation: Seizure. 2004 Dec;13 Suppl 1:S50-5; discussion S56
references.pmid: 15511692
references.citation: Seizure. 2015 Feb;25:52-61
references.pmid: 25645637
references.citation: Handb Exp Pharmacol. 2011;205:339-51
references.pmid: 21882120
references.citation: Epilepsia. 2014 Oct;55(10):1534-43
references.pmid: 25109239
references.citation: Clin Neuropharmacol. 1999 Jul-Aug;22(4):192-200
references.pmid: 10442247
references.citation: Lancet Neurol. 2012 Sep;11(9):792-802
references.pmid: 22832500
references.citation: Epilepsy Res. 2011 Sep;96(1-2):39-44
references.pmid: 21601427
references.citation: Pharmacogenomics. 2013 Nov;14(15):1821-31
references.pmid: 24236482
references.citation: Seizure. 2004 Dec;13 Suppl 1:S41-8; discussion S49
references.pmid: 15511689
references.citation: Drug Saf. 2013 Mar;36(3):183-97
references.pmid: 23377696
references.citation: Acta Neurol Scand Suppl. 2012;(194):19-28
references.pmid: 23106522
references.citation: Acta Neurol Scand. 2008 Aug;118(2):87-93
references.pmid: 18547272
references.citation: Seizure. 2007 Jun;16(4):296-304
references.pmid: 17267243
references.citation: Neuropsychiatr Dis Treat. 2009;5:249-59
references.pmid: 19557119
references.citation: Lancet Neurol. 2012 Jul;11(7):579-88
references.pmid: 22683226
references.citation: Seizure. 1996 Sep;5(3):199-203
references.pmid: 8902921
references.citation: J Clin Neurol. 2007 Dec;3(4):175-80
references.pmid: 19513128